Trial acceleration: AI supports progress, relationships drive success

Core Insights - The pharmaceutical industry faces significant delays in clinical trials due to inefficiencies in training, communication, and contract negotiations, which need to be addressed to accelerate the process [1][5][10] Group 1: Training and Communication - Sites often undergo redundant training, which delays enrollment and adds to inefficiencies [1] - Effective relationship management and open communication between sites, sponsors, and CROs are essential for efficient trial execution [3][4] - A central database for training records could help avoid duplication and streamline processes [8] Group 2: Contract Negotiations - Current practices in contract negotiations lead to inefficiencies, as sites and sponsors often start from scratch for each study [10][11] - Back-and-forth negotiations create bottlenecks, emphasizing the need for clearer communication and understanding of expectations [11] Group 3: Role of Technology - AI can assist in various areas such as site selection and data management, but foundational issues must be resolved for it to be effective [6][12] - Collaboration and early engagement with technology can help de-risk trials and improve outcomes [17][18] - Historical data and insights from previous trials can inform better protocol design, potentially reducing trial costs by 15% to 20% [13][16]